National Bank of Canada
PACB icon

National Bank of Canada’s Pacific Biosciences PACB Stock Holding History

National Bank of Canada’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,848
Closed -$1.35M – 3129
2025
Q2 		$1.35M Buy
10,848
+6,889
+174% +$7.96K ﹤0.01% 1227
2025
Q1 		$467K Buy
+3,959
New +$6.07K ﹤0.01% 1326

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

National Bank of Canada's PACB Position: Q1 2026 in Review

National Bank of Canada opened a new position in Pacific Biosciences (PACB) in Q1 2026: 198 shares worth $259. The stake represents ﹤0.01% of the portfolio and ranks #2780 among its holdings. This is a return to the name: National Bank of Canada previously reported a position in PACB as recently as Q2 2025.

National Bank of Canada first reported a position in PACB in Q4 2021 and has held it in 14 quarters since. The position peaked at $1.34M in Q2 2025. 230 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

  • National Bank of Canada held 198 shares of Pacific Biosciences worth $259 as of Q1 2026.
  • Pacific Biosciences was a new National Bank of Canada position in Q1 2026.
  • Pacific Biosciences made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #2780 holding.
  • National Bank of Canada first reported a position in Pacific Biosciences in Q4 2021 and has held it in 14 quarters since.
  • National Bank of Canada's Pacific Biosciences position peaked at $1.34M in Q2 2025.
  • 230 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.